Lawrence Eichenfield, M.D.

Bio

Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine. He is board certified in dermatology, pediatric dermatology and pediatrics.

After earning his medical degree from Mount Sinai School of Medicine in New York, Dr. Eichenfield was a pediatric resident and chief resident at Children's Hospital of Philadelphia. He then completed his dermatology residency at the Hospital of the University of Pennsylvania.

Along with longstanding expertise in atopic dermatitis, acne, psoriasis and other inflammatory skin conditions, Dr. Eichenfield has interests in neonatal dermatology, vascular lesions, laser surgery and rare skin disorders. He has authored more than 400 journal articles, chapters, abstracts and books, and has served as the senior editor of "Neonatal and Infant Dermatology," published by Elsevier, as well as "The Eczemas." He served as editor-in-chief of Pediatric Dermatology for 12 years and currently serves on the editorial boards of multiple journals and periodicals.

Dr. Eichenfield has held multiple leadership positions, including co-founder and co-chair of the Pediatric Dermatology Research Alliance, co-chair of the American Academy of Dermatology Guidelines for Atopic Dermatitis, co-chair of the American Acne and Rosacea Society/American Academy of Pediatrics Pediatric Acne Recommendations for Diagnosis and Treatment, member of the Expert Panel Member of the NIAID Guidelines for Diagnosis and Management of Food Allergy, Scientific Advisory Board of the National Eczema Association, and director of the Rady Children's/UC San Diego Eczema and Inflammatory Skin Disease Center. Additionally, he has served in leadership roles on guidelines and consensus statements for multiple dermatological conditions, including acne, rosacea, atopic dermatitis and psoriasis.

Dr. Eichenfield enjoys running, reading, and skiing.

Publications

Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis.
Eichenfield LF, Silverberg JI, Hebert AA, Boguniewicz M

Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients.
Renert-Yuval Y, Ezzedine K, Grimes P, Rosmarin D, Eichenfield LF, Castelo-Soccio L, Huang V, Desai SR, Walsh S, Silverberg JI, Paller AS, Rodrigues M, Weingarten M, Narla S, Gardner J, Siegel M, Ibad S, Silverberg NB

Risk factors and outcomes of melanoma in children and adolescents: A retrospective multicenter study.
Hawryluk EB, Moustafa D, Barry KK, Bahrani E, Reusch DB, Brahmbhatt M, Chen L, Coughlin CC, Gerami P, Haddock E, Hook K, Humphrey SR, Kao PC, Kruse LL, Lawley LP, Mansour D, Marghoob AA, Nguyen J, Phung TL, Pope E, Raisanen T, Robinson S, Rogers T, Schmidt B, Tran G, Travis K, Wolner Z, London WB, Eichenfield LF, Huang J

Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
Eichenfield LF, Stein Gold LF, Lynde C, Guenther L, Greenberger S, Chu CY, Ghodsi Z, Vlahos B, Sanders P, Cha A, Canosa JM

Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.
Eichenfield LF, Liu J, Marwaha S, Piercy J, Sturm D, Anderson P

Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paller AS, Siegfried EC, Cork MJ, Arkwright PD, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A, Cyr SL

Successful topical minoxidil treatment for hair density and length in trichorhinophalangeal syndrome type 1.
Choi M, Han A, Eichenfield LF

The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.
Bissonnette R, Simpson E, Eichenfield LF, Guttman-Yassky E, Silverberg JI, Beck LA, Mija L, Thyssen JP, Bieber T, Kabashima K, Siegfried E, Stingl G, van de Kerkhof P, Yosipovitch G, Paul C, Paller AS

Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
Eichenfield LF, Silverberg JI, Hebert AA, Chovatiya R, Brown PM, McHale KA, Rubenstein DS, Tallman AM

Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.
Eichenfield LF, Tarabar S, Forman S, García-Bello A, Feng G, Fetterly G, Mahling P, Peeva E, Vincent MS, Chandra DE

Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R

Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R

Impact of climate change on atopic dermatitis: A review by the International Eczema Council.
Wang SP, Stefanovic N, Orfali RL, Aoki V, Brown SJ, Dhar S, Eichenfield LF, Flohr C, Ha A, Mora C, Murase JE, Rosenbach M, Srinivas SM, Thyssen JP, Wei ML, Irvine AD, Abuabara K

Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris.
Eichenfield LF, Gold LS, Han J, Hebert AA, Mazzetti A, Moro L, Squittieri N, Thiboutot D

Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies.
Lie E, Choi M, Wang SP, Eichenfield LF

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.
Jacobson ME, Myles IA, Paller AS, Eichenfield LF, Simpson EL

Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
Simpson EL, Kircik L, Blauvelt A, Kallender H, Kuo Y, Ren H, Sturm D, Eichenfield LF

Treatment preferences among patients with mild-to-moderate atopic dermatitis.
Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C

Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.
Flohr C, Cork MJ, Ardern-Jones MR, Eichenfield LF, Barbarot S, Feeney C, Rojo R, Lazariciu I, Nesnas J

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, Kosloski MP, Dubost-Brama A, Prescilla R, Bansal A, Levit NA

Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials.
Stein Gold L, Lain E, Del Rosso JQ, Gold M, Draelos ZD, Eichenfield LF, Sadick N, Werschler WP, Gooderham MJ, Lupo M

A multimodal initiative improves general pediatric provider management of atopic dermatitis in children: A prospective interventional study.
Lee SS, Kaushik A, Natsis N, Kusari A, Schairer D, Lindback S, Levenberg M, Mills JR, Peeples K, Smith R, Eichenfield LF

Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
Simpson EL, Guttman-Yassky E, Eichenfield LF, Boguniewicz M, Bieber T, Schneider S, Guana A, Silverberg JI

Type VII Collagen Deficiency in the Oncogenesis of Cutaneous Squamous Cell Carcinoma in Dystrophic Epidermolysis Bullosa.
South AP, Laimer M, Gueye M, Sui JY, Eichenfield LF, Mellerio JE, Nyström A

DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial.
Eichenfield LF, DuBois JC, Gold MH, Nardo CJ, Draelos ZD, DMT310 Study Group

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.